Pancreatitis (acute)
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
What is Pancreatitis (acute)?
Pancreatic inflammation, a labeled warning on every approved GLP-1.
The mechanism looks indirect: gallstone-triggered duct obstruction rather than direct toxicity. Pooled FDA adverse-event data put incidence around 0.2–0.4% over typical treatment, against a background near 0.05% a year: elevated, still low in absolute terms. Prior pancreatitis, heavy alcohol use or symptomatic gallstones change that calculation.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Pancreatitis (acute) comes up on this site
On GLP Watchdog, Pancreatitis comes up in 2 research articles.
Research that discusses it
Connected terms
Other terms under Side effects
Where the evidence lives
- Side-effect timeline tool
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers